Find relevant news articles from other European projects, below:


Browse our carefully curated library of the latest news and developments in all areas of immunotherapy here:

Immunotherapy Web Featured Images 45

ASH 2020 | TRANSCEND CLL 04: 18-month follow-up of liso-cel for R/R CLL

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the findings of a trial (NCT03386513) of IMGN632, a novel antibody-drug conjugate (ADC), in relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN), a setting with poor outcomes and minimal treatment options.

Visit website
Immunotherapy Web Featured Images 46

ASH 2020 | Phase I trial of decitabine plus ipilimumab in R/R MDS & AML

Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the results of a Phase I trial (NCT02890329) of decitabine (DAC) in combination with ipilimumab (IPI) in patients with relapsed/refractory myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML), with or without prior allogeneic hematopoietic cell transplantation (allo-HCT).

Visit website
Immunotherapy Web Featured Images 32

EHA-SWG Scientific meeting on Immunotherapy: Checkpoint inhibition in hematologi...

  Dec 02 2020 Tagged ICI

Selected from the latest EHA-SWG Scientific Meeting on Immunotherapy, we present two lectures covering the use of immune checkpoint inhibitors (ICIs) in hematology. Peter Brossart explains the mechanism of action of these drugs and Paul Bröckelmann gives an updated overview of approved and emerging indications.  

Read more
Immunotherapy Web Featured Images 35

CAR T-Cell Therapy Improves Blood Cancer, But Toxicities Are Still Concerning

  Nov 29 2020 Tagged CAR-T, Nurses

In an interview with OncLive, during the 2020 Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Olalekan O. Oluwole, MBBS, MD, who is an assistant professor of medicine, hematology, and oncology at Vanderbilt-Ingram Cancer Center, highlighted the evolution of CAR T-cell therapy in leukemia and lymphoma, targets under investigation, and next steps for exploration.

Visit website
Immunotherapy Web Featured Images 7

Highlights in the myeloma field to come at ASH 2020

  Nov 27 2020 Tagged MM, CAR-T, mAbs

Enrique M. Ocio, MD, PhD, Marqués de Valdecilla University Hospital, Santander, Spain, shares what highlights there are to look forward to in the multiple myeloma field at ASH 2020

Visit website
Immunotherapy Web Featured Images 33

iwCAR-T meeting 2020: featured sessions

  Nov 26 2020 Tagged CAR-T, NHL, ALL, AML, MM, CLL

During iwCAR-T 2020, some of the world’s leading clinical researchers shared their perspectives on how to place our evolving understanding in a clinical context and thereby optimize clinical care.

Visit website

Should all Elderly Patients with Newly Diagnosed Multiple Myeloma Receive Monoc...

  Nov 25 2020 Tagged MM, mAbs

In light of the recent approvals of combination anti-myeloma regimens containing monoclonal antibodies, as well as the robust pipeline of novel targeted agents likely to be approved in the next year, there is much optimism in the field of multiple myeloma.

Visit website

CAR T-Cell Combinations May Offer a Way to Overcome Antigen Escape in MCL

Joshua Brody, MD, discusses advances made with CAR T-cell therapy in MCL, the promise of venetoclax in B-cell malignancies, and the potential for bispecific antibody combination regimens in this disease.

Visit website
Immunotherapy Web Featured Images 25

EHA and EBMT join forces in the GoCART coalition to advance cellular therapy in ...

EHA joins EBMT in a newly founded GoCART coalition aimed at positioning Europe in the lead of the global cellular therapy field for hematological diseases. GoCART aims to promote patient access to novel cellular therapies and to contribute health and well-being through innovation by multi-stakeholder collaboration.

Read more

CAR T-Cell Research Surges

  Nov 15 2020 Tagged CAR-T

Research on chimeric antigen receptor (CAR) T-cell therapies has exploded since the first such treatment received approval in 2017. Hundreds of trials are under way, 3 therapies for hematologic malignancies are on the market, and 2 new products may receive FDA approval in the next several months, including a BCMA–directed therapy that is poised to help transform treatment of multiple myeloma (MM).

Visit website